Taiwan Rare-disease medicines companies and pipeline landscape (November 2026) | Drugnews
At least 2 Taiwanese biotech companies are active in Rare-disease medicines, with 2 assets in development or on the market. The most advanced is Excelsior (6496)’s EX044 (Pipeline chart shows Phase III; Wilson disease). Data as of 2026-11-01; updated as new information becomes available.
Taiwan pipelines
2 / 2
| Excelsior (6496) | 6496 | EX044 | Not disclosed | Pipeline chart shows Phase III; trial status undisclosed | Wilson disease | Not disclosed | 2025-12-16 | 2025-12-16 |
| TSH (8432) | 8432 | GASA25 | Not disclosed | Rare-disease designation and marketing application planned | Rare disease; specific disease not disclosed | Not disclosed | 2026-04-24 | 2026-04-24 |
No matches. Clear the search to show all rows.
Recent events
Related Drugnews analysis
FAQ
Which Taiwanese companies are developing Rare-disease medicines?
Currently, 2 companies are included: Excelsior (6496), TSH (8432). Their drugs, stages and indications are in the pipeline table above.
Which Taiwan-listed stocks are linked to Rare-disease medicines?
Taiwan-listed companies directly involved in Rare-disease medicines R&D, manufacturing or licensing include: Excelsior (6496), TSH (8432). Compiled from public information; this is not investment advice.
Which Taiwanese Rare-disease medicines program is most advanced?
Excelsior (6496)’s EX044 is at Pipeline chart shows Phase III (Wilson disease).
What is the latest important development in Taiwan’s Rare-disease medicines sector?
The latest record is 2026-04-24: TSH (8432) Published source records GASA25: Rare-disease designation and marketing application planned..
SourceHow often is this data updated?
Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.